Literature DB >> 12824002

Proteolytic signaling by TNFalpha: caspase activation and IkappaB degradation.

Xiaotang Hu1.   

Abstract

Following binding its death receptor on the plasma membrane, tumor necrosis factor (TNF) induces the receptor trimerization and recruits a number of death domain-containing molecules to form the receptor complex. The complex promotes activation of downstream caspase cascade and induces degradation of IkappaBalpha. Caspases are activated using mechanisms of oligomeration and 'self-controlled proteolysis'. According to their structures and functions, apoptosis related caspases can be divided into upstream and downstream caspases. In general, upstream caspases cleave and activate downstream caspases by proteolysis of the Asp-X site. Activated caspases then cleaved target substrates. To date, more than 70 proteins have been identified to be substrates of caspases in mammalian cells. Caspases can alter the function of their target proteins by destroying structural components of the cytoskeleton and nuclear scaffold or by removing their regulatory domains. Activation of NF-kappaB is dependent on the degradation of IkappaBalpha. IkappaB kinase (IKK) phosphorylates IkappaBalpha at the residues 32 and 36 followed by polyubiquitination at lysine 21 and 22 and subsequent degradation of the molecules by 26S proteasome. There is extensive crosstalk between the apoptotic and NF-kappaB signaling pathways that emanate from TNF-R1. On the one hand, activation of NF-kappaB can inactivate caspases; on the other hand, activated caspases can inhibit the activation of NF-kappaB. Both processes involve in proteolysis. This crosstalk may be important for maintaining the balance between the two pathways and for determining whether a cell should live or die.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824002     DOI: 10.1016/s1043-4666(03)00107-8

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells.

Authors:  Vladimir Jurisic; Tatjana Srdic-Rajic; Gordana Konjevic; Gordana Bogdanovic; Mija Colic
Journal:  J Membr Biol       Date:  2011-01-11       Impact factor: 1.843

2.  Caspase-8 prevents sustained activation of NF-kappaB in monocytes undergoing macrophagic differentiation.

Authors:  Cédric Rébé; Séverine Cathelin; Sophie Launay; Rodolphe Filomenko; Laurent Prévotat; Coralie L'Ollivier; Emmanuel Gyan; Olivier Micheau; Steven Grant; Anne Dubart-Kupperschmitt; Michaëla Fontenay; Eric Solary
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

3.  TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}.

Authors:  Ya-Qin Zhu; Xiao-Di Tan
Journal:  Am J Physiol Cell Physiol       Date:  2005-07-13       Impact factor: 4.249

4.  Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Authors:  Chunyang Li; Shuzhen Chen; Ping Yue; Xingming Deng; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

5.  Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells.

Authors:  Ji Yeon Lee; Man Hee Rhee; Jae Youl Cho
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-26       Impact factor: 3.000

Review 6.  Cellular and molecular basis for endometriosis-associated infertility.

Authors:  Julie A W Stilley; Julie A Birt; Kathy L Sharpe-Timms
Journal:  Cell Tissue Res       Date:  2012-09       Impact factor: 5.249

7.  Sex Differences of Human Cardiac Progenitor Cells in the Biological Response to TNF-α Treatment.

Authors:  Elisabetta Straface; Lucrezia Gambardella; Francesca Pagano; Francesco Angelini; Barbara Ascione; Rosa Vona; Elena De Falco; Elena Cavarretta; Raffaele La Russa; Walter Malorni; Giacomo Frati; Isotta Chimenti
Journal:  Stem Cells Int       Date:  2017-09-17       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.